Neuropeptide Y and its role in CNS disease and repair

Experimental Neurology

Volumn 238, Issue 2, 2012, Pages 265-272

  Decressac, M ^a   Barker, R A ^b  

^a LUND UNIVERSITY   (Sweden)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Neurodegenerative diseases; Neurogenesis; Neuropeptide Y; Neuroprotection

Indexed keywords

NEUROPEPTIDE Y;

ALZHEIMER DISEASE; BINDING AFFINITY; BINDING SITE; BRAIN REGION; CELL PROLIFERATION; CELL STIMULATION; CENTRAL NERVOUS SYSTEM DISEASE; DISEASE ACTIVITY; DISEASE ASSOCIATION; HIPPOCAMPUS; HUMAN; HUNTINGTON CHOREA; MOLECULAR PATHOLOGY; NERVE DEGENERATION; NERVOUS SYSTEM DEVELOPMENT; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN LOCALIZATION; REVIEW; SUBVENTRICULAR ZONE;

ANIMALS; CENTRAL NERVOUS SYSTEM DISEASES; GENE EXPRESSION REGULATION; HUMANS; MICROTUBULE-ASSOCIATED PROTEINS; NEUROGENESIS; NEUROPEPTIDE Y; NEUROPEPTIDES; NEUROPROTECTIVE AGENTS; SIGNAL TRANSDUCTION;

EID: 84867003392     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2012.09.004     Document Type: Review

References (92)

1. Adewale A.S., Macarthur H., Westfall T.C. Neuropeptide Y induced modulation of dopamine synthesis in the striatum. Regul. Pept. 2005, 129:73-78.
2. Adewale A.S., Macarthur H., Westfall T.C. Neuropeptide Y-induced enhancement of the evoked release of newly synthesized dopamine in rat striatum: mediation by Y2 receptors. Neuropharmacology 2007, 52:1396-1402.
3. Adrian T.E., Allen J.M., Bloom S.R., Ghatei M.A., Rossor M.N., Roberts G.W., Crow T.J., Tatemoto K., Polak J.M. Neuropeptide Y distribution in human brain. Nature 1983, 306:584-586.
4. Agasse F., Bernardino L., Kristiansen H., Christiansen S.H., Ferreira R., Silva B., Grade S., Woldbye D.P., Malva J.O. Neuropeptide Y promotes neurogenesis in murine subventricular zone. Stem Cells 2008, 26:1636-1645.
5. Allen Y.S., Adrian T.E., Allen J.M., Tatemoto K., Crow T.J., Bloom S.R., Polak J.M. Neuropeptide Y distribution in the rat brain. Science 1983, 221:877-879.
6. Allen Y.S., Bloom S.R., Polak J.M. The neuropeptide Y-immunoreactive neuronal system: discovery, anatomy and involvement in neurodegenerative disease. Hum. Neurobiol. 1986, 5:227-234.
7. Baraban S.C., Hollopeter G., Erickson J.C., Schwartzkroin P.A., Palmiter R.D. Knock-out mice reveal a critical antiepileptic role for neuropeptide Y. J. Neurosci. 1997, 17:8927-8936.
8. Batista C.M., Kippin T.E., Willaime-Morawek S., Shimabukuro M.K., Akamatsu W., van der Kooy D. A progressive and cell non-autonomous increase in striatal neural stem cells in the Huntington's disease R6/2 mouse. J. Neurosci. 2006, 26:10452-10460.
9. Beal M.F., Frank R.C., Ellison D.W., Martin J.B. The effect of neuropeptide Y on striatal catecholamines. Neurosci. Lett. 1986, 71:118-123.
10. Beal M.F., Kowall N.W., Ellison D.W., Mazurek M.F., Swartz K.J., Martin J.B. Replication of the neurochemical characteristics of Huntington's disease by quinolinic acid. Nature 1986, 321:168-171.
11. Beal M.F., Mazurek M.F., Chattha G.K., Svendsen C.N., Bird E.D., Martin J.B. Neuropeptide Y immunoreactivity is reduced in cerebral cortex in Alzheimer's disease. Ann. Neurol. 1986, 20:282-288.
12. Beal M.F., Mazurek M.F., Ellison D.W., Swartz K.J., McGarvey U., Bird E.D., Martin J.B. Somatostatin and neuropeptide Y concentrations in pathologically graded cases of Huntington's disease. Ann. Neurol. 1988, 23:562-569.
13. Cannizzaro C., Tel B.C., Rose S., Zeng B.Y., Jenner P. Increased neuropeptide Y mRNA expression in striatum in Parkinson's disease. Brain Res. Mol. Bain Res. 2003, 110:169-176.
14. Chan-Palay V., Lang W., Allen Y.S., Haesler U., Polak J.M. Cortical neurons immunoreactive with antisera against neuropeptide Y are altered in Alzheimer's-type dementia. J. Comp. Neurol. 1985, 238:390-400.
15. Chan-Palay V., Lang W., Haesler U., Kohler C., Yasargil G. Distribution of altered hippocampal neurons and axons immunoreactive with antisera against neuropeptide Y in Alzheimer's-type dementia. J. Comp. Neurol. 1986, 248:376-394.
16. Chee M.J., Colmers W.F. Y eat?. Nutrition 2008, 24:869-877.
17. Colmers W.F., Lukowiak K., Pittman Q.J. Neuropeptide Y action in the rat hippocampal slice: site and mechanism of presynaptic inhibition. J. Neurosci. 1988, 8:3827-3837.
18. Colmers W.F., Klapstein G.J., Fournier A., St-Pierre S., Treherne K.A. Presynaptic inhibition by neuropeptide Y in rat hippocampal slice in vitro is mediated by a Y2 receptor. Br. J. Pharmacol. 1991, 102:41-44.
19. Croce N., Dinallo V., Ricci V., Federici G., Caltagirone C., Bernardini S., Angelucci F. Neuroprotective effect of neuropeptide Y against beta-amyloid 25-35 toxicity in SH-SY5Y neuroblastoma cells is associated with increased neurotrophin production. Neurodegener. Dis. 2011, 8:300-309.
20. Croce N., Ciotti M.T., Gelfo F., Cortelli S., Federici G., Caltagirone C., Bernardini S., Angelucci F. Neuropeptide Y protect rat cortical neurons against β-amyloid toxicity and re-establishes synthesis and release of nerve growth factor. ACS Chem. Neurosci. 2012, 3:312-318.
21. Curtis M.A., Penney E.B., Pearson A.G., van Roon-Mom W.M., Butterworth N.J., Dragunow M., Connor B., Faull R.L. Increased cell proliferation and neurogenesis in the adult human Huntington's disease brain. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:9023-9027.
22. Curtis M.A., Faull R.L., Eriksson P.S. The effect of neurodegenerative diseases on the subventricular zone. Nat. Rev. Neurosci. 2007, 8:712-723.
23. Dawbarn D., De Quidt M.E., Emson P.C. Survival of basal ganglia neuropeptide Y-somatostatin neurones in Huntington's disease. Brain Res. 1985, 340:251-260.
24. Decressac M., Prestoz L., Veran J., Cantereau A., Jaber M., Gaillard A. Neuropeptide Y stimulates proliferation, migration and differentiation of neural precursors from the subventricular zone in adult mice. Neurobiol. Dis. 2009, 34:441-449.
25. Decressac M., Wright B., Tyers P., Gaillard A., Barker R.A. Neuropeptide Y modifies the disease course in the R6/2 transgenic model of Huntington's disease. Exp. Neurol. 2010, 226:24-32.
26. Decressac M., Wright B., Tyers P., Gaillard A., Barker R.A. Neuropeptide Y modifies the disease course in the R6/2 transgenic model of Huntington's disease. Exp. Neurol. 2010, 226:24-32.
27. Decressac M., Wright B., David B., Tyers P., Jaber M., Barker R.A., Gaillard A. Exogenous neuropeptide Y promotes in vivo hippocampal neurogenesis. Hippocampus 2011, 21:233-238.
28. Decressac M., Pain S., Chabeauti P.Y., Frangeul L., Thiriet N., Herzog H., Vergote J., Chalon S., Jaber M., Gaillard A. Neuroprotection by neuropeptide Y in cell and animal models of Parkinson's disease. Neurobiol. Aging 2011.
29. Deng W., Aimone J.B., Gage F.H. New neurons and new memories: how does adult hippocampal neurogenesis affect learning and memory?. Nat. Rev. Neurosci. 2010, 11:339-350.
30. Dumont Y., Jacques D., Bouchard P., Quirion R. Species differences in the expression and distribution of the neuropeptide Y Y1, Y2, Y4, and Y5 receptors in rodents, guinea pig, and primates brains. J. Comp. Neurol. 1998, 402:372-384.
31. Edvinsson L., Minthon L., Ekman R., Gustafson L. Neuropeptides in cerebrospinal fluid of patients with Alzheimer's disease and dementia with frontotemporal lobe degeneration. Dementia 1993, 4:167-171.
32. Erickson J.C., Clegg K.E., Palmiter R.D. Sensitivity to leptin and susceptibility to seizures of mice lacking neuropeptide Y. Nature 1996, 381:415-421.
33. Ferreira R., Xapelli S., Santos T., Silva A.P., Cristovao A., Cortes L., Malva J.O. Neuropeptide Y modulation of interleukin-1{beta} (IL-1{beta})-induced nitric oxide production in microglia. J. Biol. Chem. 2010, 285:41921-41934.
34. Ferreira R., Santos T., Viegas M., Cortes L., Bernardino L., Vieira O.V., Malva J.O. Neuropeptide Y inhibits interleukin-1β-induced phagocytosis by microglial cells. J. Neuroinflammation 2011, 8:169.
35. Ferreira R., Santos T., Cortes L., Cochaud S., Agasse F., Silva A.P., Xapelli S., Malva J.O. Neuropeptide Y inhibits interleukin-1 beta-induced microglia motility. J. Neurochem. 2012, 120:93-105.
36. Furtinger S., Pirker S., Czech T., Baumgartner C., Ransmayr G., Sperk G. Plasticity of Y1 and Y2 receptors and neuropeptide Y fibers in patients with temporal lobe epilepsy. J. Neurosci. 2001, 21:5804-5812.
37. Furtinger S., Pirker S., Czech T., Baumgartner C., Sperk G. Altered expression of neuropeptide Y, -Y(1), and -Y(2) receptors in the hippocampus of patients with mesial temporal lobe epilepsy. Epilepsia 2002, 43(Suppl. 5):152.
38. Glass C.K., Saijo K., Winner B., Marchetto M.C., Gage F.H. Mechanisms underlying inflammation in neurodegeneration. Cell 2010, 140:918-934.
39. Hansel D.E., Eipper B.A., Ronnett G.V. Neuropeptide Y functions as a neuroproliferative factor. Nature 2001, 410:940-944.
40. Hokfelt T., Stanic D., Sanford S.D., Gatlin J.C., Nilsson I., Paratcha G., Ledda F., Fetissov S., Lindfors C., Herzog H., Johansen J.E., Ubink R., Pfenninger K.H. NPY and its involvement in axon guidance, neurogenesis, and feeding. Nutrition 2008, 24:860-868.
41. Howell O.W., Scharfman H.E., Herzog H., Sundstrom L.E., Beck-Sickinger A., Gray W.P. Neuropeptide Y is neuroproliferative for post-natal hippocampal precursor cells. J. Neurochem. 2003, 86:646-659.
42. Howell O.W., Doyle K., Goodman J.H., Scharfman H.E., Herzog H., Pringle A., Beck-Sickinger A.G., Gray W.P. Neuropeptide Y stimulates neuronal precursor proliferation in the post-natal and adult dentate gyrus. J. Neurochem. 2005, 93:560-570.
43. Howell O.W., Silva S., Scharfman H.E., Sosunov A.A., Zaben M., Shatya A., McKhann G., Herzog H., Laskowski A., Gray W.P. Neuropeptide Y is important for basal and seizure-induced precursor cell proliferation in the hippocampus. Neurobiol. Dis. 2007, 26:174-188.
44. Imarisio S., Carmichael J., Korolchuk V., Chen C.W., Saiki S., Rose C., Krishna G., Davies J.E., Ttofi E., Underwood B.R., Rubinsztein D.C. Huntington's disease: from pathology and genetics to potential therapies. Biochem. J. 2008, 412:191-209.
45. Jia C., Hegg C.C. NPY mediates ATP-induced neuroproliferation in adult mouse olfactory epithelium. Neurobiol. Dis. 2010, 38:405-413.
46. Jia C., Hegg C.C. Neuropeptide Y and extracellular signal-regulated kinase mediate injury-induced neuroregeneration in mouse olfactory epithelium. Mol. Cell. Neurosci. 2011, 49:158-170.
47. Jin K., Peel A.L., Mao X.O., Xie L., Cottrell B.A., Henshall D.C., Greenberg D.A. Increased hippocampal neurogenesis in Alzheimer's disease. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:343-347.
48. Kerkerian L., Bosler O., Pelletier G., Nieoullon A. Striatal neuropeptide Y neurones are under the influence of the nigrostriatal dopaminergic pathway: immunohistochemical evidence. Neurosci. Lett. 1986, 66:106-112.
49. Kerkerian L., Salin P., Nieoullon A. Cortical regulation of striatal neuropeptide Y (NPY)-containing neurons in the rat. Eur. J. Neurosci. 1990, 2:181-189.
50. Kerkerian L., Salin P., Nieoullon A. Cortical regulation of striatal neuropeptide Y (NPY)-containing neurons in the rat. Eur. J. Neurosci. 1990, 2:181-189.
51. Kerkerian-Le Goff L., Forni C., Samuel D., Bloc A., Dusticier N., Nieoullon A. Intracerebroventricular administration of neuropeptide Y affects parameters of dopamine, glutamate and GABA activities in the rat striatum. Brain Res. Bull. 1992, 28:187-193.
52. Kokaia M. Seizure-induced neurogenesis in the adult brain. Eur. J. Neurosci. 2011, 33:1133-1138.
53. Kopp J., Xu Z.Q., Zhang X., Pedrazzini T., Herzog H., Kresse A., Wong H., Walsh J.H., Hokfelt T. Expression of the neuropeptide Y Y1 receptor in the CNS of rat and of wild-type and Y1 receptor knock-out mice. Focus on immunohistochemical localization. Neuroscience 2002, 111:443-532.
54. Laskowski A., Howell O.W., Sosunov A.A., McKhann G., Gray W.P. NPY mediates basal and seizure-induced proliferation in the subcallosal zone. Neuroreport 2007, 18:1005-1008.
55. Lee S.J., Lim H.S., Masliah E., Lee H.J. Protein aggregate spreading in neurodegenerative diseases: problems and perspectives. Neurosci. Res. 2011, 70:339-348.
56. Lin S., Boey D., Herzog H. NPY and Y receptors: lessons from transgenic and knockout models. Neuropeptides 2004, 38:189-200.
57. Maeda K., Yasuda M., Kaneda H., Maeda S., Yamadori A. Cerebrospinal fluid (CSF) neuropeptide Y- and somatostatin-like immunoreactivities in man. Neuropeptides 1994, 27:323-332.
58. Martignoni E., Blandini F., Petraglia F., Pacchetti C., Bono G., Nappi G. Cerebrospinal fluid norepinephrine, 3-methoxy-4-hydroxyphenylglycol and neuropeptide Y levels in Parkinson's disease, multiple system atrophy and dementia of the Alzheimer type. J. Neural Transm. Park. Dis. Dement. Sect. 1992, 4:191-205.
59. Mazurek M.F., Garside S., Beal M.F. Cortical peptide changes in Huntington's disease may be independent of striatal degeneration. Ann. Neurol. 1997, 41:540-547.
60. Michel M.C., Beck-Sickinger A., Cox H., Doods H.N., Herzog H., Larhammar D., Quirion R., Schwartz T., Westfall T. XVI. International Union of Pharmacology recommendations for the nomenclature of neuropeptide Y, peptide YY, and pancreatic polypeptide receptors. Pharmacol. Rev. 1998, 50:143-150.
61. Minthon L., Edvinsson L., Ekman R., Gustafson L. Neuropeptide levels in Alzheimer's disease and dementia with frontotemporal degeneration. J. Neural Transm. Suppl. 1990, 30:57-67.
62. Moukhles H., Nieoullon A., Daszuta A. Early and widespread normalization of dopamine-neuropeptide Y interactions in the rat striatum after transplantation of fetal mesencephalon cells. Neuroscience 1992, 47:781-792.
63. Naveilhan P., Neveu I., Arenas E., Ernfors P. Complementary and overlapping expression of Y1, Y2 and Y5 receptors in the developing and adult mouse nervous system. Neuroscience 1998, 87:289-302.
64. Noe F., Pool A.H., Nissinen J., Gobbi M., Bland R., Rizzi M., Balducci C., Ferraguti F., Sperk G., During M.J., Pitkanen A., Vezzani A. Neuropeptide Y gene therapy decreases chronic spontaneous seizures in a rat model of temporal lobe epilepsy. Brain 2008, 131:1506-1515.
65. Obuchowicz E., Antkiewicz-Michaluk L., Romanska I., Herman Z.S. Increased striatal neuropeptide Y immunoreactivity and its modulation by deprenyl, clonidine and L-dopa in MPTP-treated mice. J. Neural Transm. 2003, 110:1375-1391.
66. O'Keeffe G.C., Barker R.A., Caldwell M.A. Dopaminergic modulation of neurogenesis in the subventricular zone of the adult brain. Cell Cycle 2009, 8:2888-2894.
67. Pedrazzini T., Pralong F., Grouzmann E. Neuropeptide Y: the universal soldier. Cell. Mol. Life Sci. 2003, 60:350-377.
68. Phillips W., Morton A.J., Barker R.A. Abnormalities of neurogenesis in the R6/2 mouse model of Huntington's disease are attributable to the in vivo microenvironment. J. Neurosci. 2005, 25:11564-11576.
69. Ramos B., Baglietto-Vargas D., del Rio J.C., Moreno-Gonzalez I., Santa-Maria C., Jimenez S., Caballero C., Lopez-Tellez J.F., Khan Z.U., Ruano D., Gutierrez A., Vitorica J. Early neuropathology of somatostatin/NPY GABAergic cells in the hippocampus of a PS1xAPP transgenic model of Alzheimer's disease. Neurobiol. Aging 2006, 27:1658-1672.
70. Rancillac A., Laine J., Perrenoud Q., Geoffroy H., Ferezou I., Vitalis T., Rossier J. Degenerative abnormalities in transgenic neocortical neuropeptide Y interneurons expressing tau-green fluorescent protein. J. Neurosci. Res. 2010, 88:487-499.
71. Riban V., Fitzsimons H.L., During M.J. Gene therapy in epilepsy. Epilepsia 2009, 50:24-32.
72. Rodrigo C., Zaben M., Lawrence T., Laskowski A., Howell O.W., Gray W.P. NPY augments the proliferative effect of FGF2 and increases the expression of FGFR1 on nestin positive postnatal hippocampal precursor cells, via the Y1 receptor. J. Neurochem. 2010, 113:615-627.
73. Rose J.B., Crews L., Rockenstein E., Adame A., Mante M., Hersh L.B., Gage F.H., Spencer B., Potkar R., Marr R.A., Masliah E. Neuropeptide Y fragments derived from neprilysin processing are neuroprotective in a transgenic model of Alzheimer's disease. J. Neurosci. 2009, 29:1115-1125.
74. Rylander D., Iderberg H., Li Q., Dekundy A., Zhang J., Li H., Baishen R., Danysz W., Bezard E., Cenci M.A. A mGluR5 antagonist under clinical development improves L-DOPA-induced dyskinesia in parkinsonian rats and monkeys. Neurobiol. Dis. 2010, 39:352-361.
75. Salin P., Kerkerian L., Nieoullon A. Expression of neuropeptide Y immunoreactivity in the rat nucleus accumbens is under the influence of the dopaminergic mesencephalic pathway. Exp. Brain Res. 1990, 81:363-371.
76. Sanai N., Nguyen T., Ihrie R.A., Mirzadeh Z., Tsai H.H., Wong M., Gupta N., Berger M.S., Huang E., Garcia-Verdugo J.M., Rowitch D.H., Alvarez-Buylla A. Corridors of migrating neurons in the human brain and their decline during infancy. Nature 2011, 478:382-386.
77. Sananbenesi F., Fischer A. The epigenetic bottleneck of neurodegenerative and psychiatric diseases. Biol. Chem. 2009, 390:1145-1153.
78. Shaw J.L., Gackenheimer S.L., Gehlert D.R. Functional autoradiography of neuropeptide Y Y1 and Y2 receptor subtypes in rat brain using agonist stimulated [35S]GTPgammaS binding. J. Chem. Neuroanat. 2003, 26:179-193.
79. Sorensen A.T., Kanter-Schlifke I., Lin E.J., During M.J., Kokaia M. Activity-dependent volume transmission by transgene NPY attenuates glutamate release and LTP in the subiculum. Mol. Cell. Neurosci. 2008, 39:229-237.
80. Sperk G., Hamilton T., Colmers W.F. Neuropeptide Y in the dentate gyrus. Prog. Brain Res. 2007, 163:285-297.
81. Stanic D., Paratcha G., Ledda F., Herzog H., Kopin A.S., Hokfelt T. Peptidergic influences on proliferation, migration, and placement of neural progenitors in the adult mouse forebrain. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:3610-3615.
82. Stanic D., Mulder J., Watanabe M., Hokfelt T. Characterization of NPY Y2 receptor protein expression in the mouse brain. II. Coexistence with NPY, the Y1 receptor, and other neurotransmitter-related molecules. J. Comp. Neurol. 2011, 519:1219-1257.
83. Suh H., Deng W., Gage F.H. Signaling in adult neurogenesis. Annu. Rev. Cell Dev. Biol. 2009, 25:253-275.
84. Tatemoto K. Neuropeptide Y: complete amino acid sequence of the brain peptide. Proc. Natl. Acad. Sci. U. S. A. 1982, 79:5485-5489.
85. Tatemoto K., Carlquist M., Mutt V. Neuropeptide Y-a novel brain peptide with structural similarities to peptide YY and pancreatic polypeptide. Nature 1982, 296:659-660.
86. Thiriet N., Agasse F., Nicoleau C., Guegan C., Vallette F., Cadet J.L., Jaber M., Malva J.O., Coronas V. NPY promotes chemokinesis and neurogenesis in the rat subventricular zone. J. Neurochem. 2011, 116:1018-1027.
87. Vuillet J., Kerkerian L., Kachidian P., Bosler O., Nieoullon A. Ultrastructural correlates of functional relationships between nigral dopaminergic or cortical afferent fibers and neuropeptide Y-containing neurons in the rat striatum. Neurosci. Lett. 1989, 100:99-104.
88. Wilcock D.M., Lewis M.R., Van Nostrand W.E., Davis J., Previti M.L., Gharkholonarehe N., Vitek M.P., Colton C.A. Progression of amyloid pathology to Alzheimer's disease pathology in an amyloid precursor protein transgenic mouse model by removal of nitric oxide synthase 2. J. Neurosci. 2008, 28:1537-1545.
89. Woldbye D.P., Angehagen M., Gotzsche C.R., Elbrond-Bek H., Sorensen A.T., Christiansen S.H., Olesen M.V., Nikitidou L., Hansen T.V., Kanter-Schlifke I., Kokaia M. Adeno-associated viral vector-induced overexpression of neuropeptide Y Y2 receptors in the hippocampus suppresses seizures. Brain 2010, 133:2778-2788.
90. Woodhams P.L., Allen Y.S., McGovern J., Allen J.M., Bloom S.R., Balazs R., Polak J.M. Immunohistochemical analysis of the early ontogeny of the neuropeptide Y system in rat brain. Neuroscience 1985, 15:173-202.
91. Xapelli S., Agasse F., Ferreira R., Silva A.P., Malva J.O. Neuropeptide Y as an endogenous antiepileptic, neuroprotective and pro-neurogenic peptide. Recent Pat. CNS Drug Discov. 2006, 1:315-324.
92. Yaksh T.L., Carmichael S.W., Stoddard S.L., Tyce G.M., Kelly P.J., Lucas D., van Heerden J.A., Ahlskog J.E., Byer D.E. Measurement of lumbar CSF levels of met-enkephalin, encrypted met-enkephalin, and neuropeptide Y in normal patients and in patients with Parkinson's disease before and after autologous transplantation of adrenal medulla into the caudate nucleus. J. Lab. Clin. Med. 1990, 115:346-351.